BID | 76.25 | ASK | 85.81 | ||
Open | 83.15 | Previous Close | 82.66 | ||
Pre-Market | - | After-Market | - | ||
- - | - -% |
Target Price | 93.75 | Analyst Rating | Strong Buy 1.54 | |
Potential % | 10.39 | Finscreener Ranking | ★★★ 49.57 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★ 47.03 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ 59.99 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★+ 39.07 | |
Market Cap | 8.43B | Earnings Rating | Sell | |
Price Range Ratio 52W % | 88.14 | Earnings Date | 27th Apr 2021 |
Today's Price Range 83.1585.60 | 52W Range 58.9988.42 | 5 Year PE Ratio Range 13.3029.10 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | 4.03% | ||
1 Month | 6.50% | ||
3 Months | 1.81% | ||
6 Months | 24.79% | ||
1 Year | 21.23% | ||
3 Years | 46.70% | ||
5 Years | 145.37% | ||
10 Years | 292.14% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 25.75 | |||
ROE last 12 Months | 18.51 | |||
ROA (5Y Avg) | 4.73 | |||
ROA last 12 Months | 4.33 | |||
ROC (5Y Avg) | 9.98 | |||
ROC last 12 Months | 7.84 | |||
Return on invested Capital Q | 2.29 | |||
Return on invested Capital Y | 8.68 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 5.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
28.70 | ||||
5.12 | ||||
2.33 | ||||
11.60 | ||||
29.90 | ||||
7.06 | ||||
-7.00 | ||||
16.00 | ||||
11.45B | ||||
Forward PE | 20.25 | |||
PEG | 1.84 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.10 | ||||
1.30 | ||||
0.69 | ||||
2.23 | ||||
3.60 | ||||
Leverage Ratio | 4.30 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
95.60 | ||||
14.10 | ||||
19.40 | ||||
12.40 | ||||
7.45 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.46B | ||||
34.88 | ||||
5.31 | ||||
7.49 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.38 | ||||
1.12 | ||||
14.40 | ||||
10.55 | ||||
Payout ratio | 41.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q04 2020 | 0.86 | 0.93 | 8.14 |
Q03 2020 | 0.75 | 0.78 | 4.00 |
Q02 2020 | 0.39 | 0.31 | -20.51 |
Q01 2020 | 0.87 | 0.87 | 0.00 |
Q04 2019 | 0.87 | 0.85 | -2.30 |
Q03 2019 | 0.89 | 0.93 | 4.49 |
Q02 2019 | 0.97 | 1.08 | 11.34 |
Q01 2019 | 0.89 | 1.04 | 16.85 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
3/2021 QR | 0.80 | -8.05 | Negative |
6/2021 QR | 0.82 | -7.87 | Negative |
12/2021 FY | 3.46 | -9.42 | Negative |
12/2022 FY | 4.03 | -2.89 | Negative |
Next Report Date | 27th Apr 2021 |
Estimated EPS Next Report | 0.80 |
Estimates Count | 6 |
EPS Growth Next 5 Years % | 15.60 |
Volume Overview | |
---|---|
Volume | 956.68K |
Shares Outstanding | 99.27M |
Trades Count | 12.55K |
Dollar Volume | 70.33M |
Avg. Volume | 642.21K |
Avg. Weekly Volume | 428.75K |
Avg. Monthly Volume | 606.79K |
Avg. Quarterly Volume | 659.46K |
Encompass Health Corporation (NYSE: EHC) stock closed at 84.93 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 956.74K shares and market capitalization of 8.43B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 43178 people. Encompass Health Corporation CEO is Mark J. Tarr.
The one-year performance of Encompass Health Corporation stock is 21.23%, while year-to-date (YTD) performance is 2.71%. EHC stock has a five-year performance of 145.37%. Its 52-week range is between 58.99 and 88.42, which gives EHC stock a 52-week price range ratio of 88.14%
Encompass Health Corporation currently has a PE ratio of 28.70, a price-to-book (PB) ratio of 5.12, a price-to-sale (PS) ratio of 2.33, a price to cashflow ratio of 11.60, a PEG ratio of 2.32, a ROA of 4.33%, a ROC of 7.84% and a ROE of 18.51%. The company’s profit margin is 7.45%, its EBITDA margin is 19.40%, and its revenue ttm is $3.46 Billion , which makes it $34.88 revenue per share.
Of the last four earnings reports from Encompass Health Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.80 for the next earnings report. Encompass Health Corporation’s next earnings report date is 27th Apr 2021.
The consensus rating of Wall Street analysts for Encompass Health Corporation is Strong Buy (1.54), with a target price of $93.75, which is +10.39% compared to the current price. The earnings rating for Encompass Health Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Encompass Health Corporation has a dividend yield of 1.38% with a dividend per share of $1.12 and a payout ratio of 41.00%.
Encompass Health Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 6.60, ATR14 : 2.21, CCI20 : 230.41, Chaikin Money Flow : 0.04, MACD : 0.17, Money Flow Index : 40.82, ROC : 2.57, RSI : 63.04, STOCH (14,3) : 88.81, STOCH RSI : 1.00, UO : 52.86, Williams %R : -11.19), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Encompass Health Corporation in the last 12-months were: Andrew Price (Sold 8 589 shares of value $699 145 ), Barbara Jacobsmeyer (Sold 2 500 shares of value $161 825 ), Douglas E. Coltharp (Option Excercise at a value of $568 959), Douglas E. Coltharp (Sold 23 501 shares of value $1 779 937 ), Elissa Joy Charbonneau (Sold 6 650 shares of value $500 213 ), Mark J. Tarr (Option Excercise at a value of $549 295), Mark J. Tarr (Sold 26 132 shares of value $1 618 093 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. It operates in two segments: inpatient rehabilitation and home health and hospice. The Inpatient rehabilitation segment contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas. The Home health and hospital segment provides skilled home health services through agencies concentrated in the southeastern United States and Texas, which include nursing, physical, occupational, and speech therapy, social work, and hospice services.
CEO: Mark J. Tarr
Telephone: +1 205 967-7116
Address: 9001 Liberty Parkway, Birmingham 35242, AL, US
Number of employees: 43 178
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE BZX (BATS) real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2021. All market data is provided by Barchart Solutions. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.